

# Summary of Recommendations for Childhood and Adolescent Immunization

Vaccine name and route	Schedule for routine vaccination and other guidelines (any vaccine can be given with another)	Schedule for catch-up vaccination and related issues	Contraindications and precautions (mild illness is not a contraindication)
<b>Hepatitis B (HepB)</b> <i>Give IM</i>	<ul style="list-style-type: none"> <li>Vaccinate all children age 0 through 18yrs.</li> <li>Vaccinate all newborns with monovalent vaccine prior to hospital discharge. Give dose #2 at age 1–2m and the final dose at age 6–18m (the last dose in the infant series should not be given earlier than age 24wks). After the birth dose, the series may be completed using 2 doses of single-antigen vaccine or up to 3 doses of Comvax (ages 2m, 4m, 12–15m) or Pediarix (ages 2m, 4m, 6m), which may result in giving a total of 4 doses of hepatitis B vaccine.</li> <li><b>If mother is HBsAg-positive:</b> give the newborn HBIG + dose #1 within 12hrs of birth; complete series at age 6m or, if using Comvax, at age 12–15m.</li> <li><b>If mother’s HBsAg status is unknown:</b> give the newborn dose #1 within 12hrs of birth. If mother is subsequently found to be HBsAg positive, give infant HBIG within 7d of birth and follow the schedule for infants born to HBsAg-positive mothers.</li> </ul>	<ul style="list-style-type: none"> <li>Do not restart series, no matter how long since previous dose.</li> <li>3-dose series can be started at any age.</li> <li>Minimum intervals between doses: 4wks between #1 and #2, 8wks between #2 and #3, and at least 16wks between #1 and #3 (e.g., 0-, 2-, 4m; 0-, 1-, 4m).</li> </ul> <div style="border: 1px solid black; border-radius: 10px; padding: 5px; margin-top: 10px;"> <p><b>Special Notes on Hepatitis B Vaccine (HepB)</b>  <b>Dosing of HepB:</b> Monovalent vaccine brands are interchangeable. For people age 0 through 19yrs, give 0.5 mL of either Engerix-B or Recombivax HB.  <b>Alternative dosing schedule for unvaccinated adolescents age 11 through 15yrs:</b> Give 2 doses Recombivax HB 1.0 mL (adult formulation) spaced 4–6m apart. (Engerix-B is not licensed for a 2-dose schedule.)  <b>For preterm infants:</b> Consult ACIP hepatitis B recommendations (<i>MMWR</i> 2005; 54 [RR-16]).*</p> </div>	<p><b>Contraindication</b>            Previous anaphylaxis to this vaccine or to any of its components.</p> <p><b>Precaution</b>            Moderate or severe acute illness.</p>
<b>DTaP, DT (Diphtheria, tetanus, acellular pertussis)</b> <i>Give IM</i>	<ul style="list-style-type: none"> <li>Give to children at ages 2m, 4m, 6m, 15–18m, 4–6yrs.</li> <li>May give dose #1 as early as age 6wks.</li> <li>May give #4 as early as age 12m if 6m have elapsed since #3 and the child is unlikely to return at age 15–18m.</li> <li>Do not give DTaP/DT to children age 7yrs and older.</li> <li>If possible, use the same DTaP product for all doses.</li> </ul>	<ul style="list-style-type: none"> <li>#2 and #3 may be given 4wks after previous dose.</li> <li>#4 may be given 6m after #3.</li> <li>If #4 is given before 4th birthday, wait at least 6m for #5 (age 4–6yrs).</li> <li>If #4 is given after 4th birthday, #5 is not needed.</li> </ul>	<p><b>Contraindications</b></p> <ul style="list-style-type: none"> <li>Previous anaphylaxis to this vaccine or to any of its components.</li> <li>For DTaP/Tdap only: encephalopathy within 7d after DTP/DTaP.</li> </ul> <p><b>Precautions</b></p> <ul style="list-style-type: none"> <li>Moderate or severe acute illness.</li> <li>History of Arthus reaction following a prior dose of tetanus- and/or diphtheria-toxoid-containing vaccine, including MCV4.</li> <li>Guillain-Barré syndrome (GBS) within 6wks after previous dose of tetanus-toxoid-containing vaccine.</li> </ul>
<b>Td, Tdap (Tetanus, diphtheria, acellular pertussis)</b> <i>Give IM</i>	<ul style="list-style-type: none"> <li>Give 1-time Tdap dose to adolescents age 11–12yrs if 5yrs have elapsed since last dose DTaP; then boost every 10yrs with Td.</li> <li>Give 1-time dose of Tdap to all adolescents who have not received previous Tdap. Special efforts should be made to give Tdap to people age 11yrs and older who are 1) in contact with infants younger than age 12m and 2) healthcare workers with direct patient contact.</li> <li>In pregnancy, when indicated, give Td or Tdap in 2nd or 3rd trimester. If not administered during pregnancy, give Tdap in immediate postpartum period.</li> </ul>	<ul style="list-style-type: none"> <li>If never vaccinated with tetanus- and diphtheria-containing vaccine: give Td dose #1 now, dose #2 4wks later, and dose #3 6m after #2, then give booster every 10yrs. A 1-time Tdap may be substituted for any dose in the series, preferably as dose #1. If previously received Td booster, an interval of 2yrs or less between Td and Tdap may be used.</li> </ul>	<ul style="list-style-type: none"> <li>For DTaP only: Any of these events following a previous dose of DTP/DTaP: 1) temperature of 105°F (40.5°C) or higher within 48hrs; 2) continuous crying for 3hrs or more within 48hrs; 3) collapse or shock-like state within 48hrs; 4) convulsion with or without fever within 3d.</li> <li>For DTaP/Tdap only: Unstable neurologic disorder.</li> <li>For Td in teens: Progressive neurologic disorder.</li> </ul> <p><b>Note:</b> Tdap may be given to pregnant women at the provider’s discretion.</p>
<b>Polio (IPV)</b> <i>Give SC or IM</i>	<ul style="list-style-type: none"> <li>Give to children at ages 2m, 4m, 6–18m, 4–6yrs.</li> <li>May give dose #1 as early as age 6wks.</li> <li>Not routinely recommended for U.S. residents age 18yrs and older (except certain travelers).</li> </ul>	<ul style="list-style-type: none"> <li>The final dose should be given on or after the 4th birthday and at least 6m from the previous dose.</li> <li>If dose #3 is given after 4th birthday, dose #4 is not needed if dose #3 is given at least 6m after dose #2.</li> </ul>	<p><b>Contraindication</b>            Previous anaphylaxis to this vaccine or to any of its components.</p> <p><b>Precautions</b></p> <ul style="list-style-type: none"> <li>Moderate or severe acute illness.</li> <li>Pregnancy.</li> </ul>

\*This document was adapted from the recommendations of the Advisory Committee on Immunization Practices (ACIP). To obtain copies of the recommendations, call the CDC-INFO Contact Center at (800) 232-4636; visit CDC’s website at [www.cdc.gov/vaccines/pubs/ACIP-list.htm](http://www.cdc.gov/vaccines/pubs/ACIP-list.htm); or visit the Immunization Action Coalition (IAC)

website at [www.immunize.org/acip](http://www.immunize.org/acip). This table is revised periodically. Visit IAC’s website at [www.immunize.org/childrules](http://www.immunize.org/childrules) to make sure you have the most current version.

Vaccine name and route	Schedule for routine vaccination and other guidelines (any vaccine can be given with another)	Schedule for catch-up vaccination and related issues	Contraindications and precautions (mild illness is not a contraindication)
<p><b>Seasonal Influenza</b> Trivalent inactivated influenza vaccine (TIV) <i>Give IM</i> Live attenuated influenza vaccine (LAIV) <i>Give intranasally</i></p>	<ul style="list-style-type: none"> <li>• Vaccinate all children and teens age 6m through 18yrs.</li> <li>• LAIV may be given to healthy, non-pregnant people age 2–49yrs.</li> <li>• Give 2 doses to first-time vaccinees age 6m through 8yrs, spaced 4wks apart.</li> <li>• For TIV, give 0.25 mL dose to children age 6–35m and 0.5 mL dose if age 3yrs and older.</li> </ul>		<p><b>Contraindications</b></p> <ul style="list-style-type: none"> <li>• Previous anaphylaxis to this vaccine, to any of its components, or to eggs.</li> <li>• For LAIV only: age younger than 2yrs; pregnancy; chronic pulmonary (including asthma), cardiovascular (except hypertension), renal, hepatic, neurological/neuromuscular, hematologic, or metabolic (including diabetes) disorders; immunosuppression (including that caused by medications or HIV); for children and teens ages 6m through 18yrs, current long-term aspirin therapy; for children age 2 through 4yrs, wheezing or asthma within the past 12m, per healthcare provider statement.</li> </ul> <p><b>Precautions</b></p> <ul style="list-style-type: none"> <li>• Moderate or severe acute illness.</li> <li>• History of Guillain-Barré syndrome (GBS) within 6wks of a previous influenza vaccination.</li> <li>• For LAIV only: <ul style="list-style-type: none"> <li>- Close contact with an immunosuppressed person when the person requires protective isolation.</li> <li>- Receipt of specific antivirals (i.e., amantadine, rimantadine, zanamivir, or oseltamivir) 48hrs before vaccination. Avoid use of these antiviral drugs for 14d after vaccination.</li> </ul> </li> </ul>
<p><b>Varicella (Var)</b> (Chickenpox) <i>Give SC</i></p>	<ul style="list-style-type: none"> <li>• Give dose #1 at age 12–15m.</li> <li>• Give dose #2 at age 4–6yrs. Dose #2 may be given earlier if at least 3m since dose #1.</li> <li>• Give a 2nd dose to all older children and adolescents with history of only 1 dose.</li> <li>• MMRV may be used in children age 12m through 12yrs.</li> <li>• MMRV generally is preferred over separate injections of its separate components in children receiving their first dose at ages 4 through 12yrs or their second dose at any age through 12yrs.</li> </ul>	<ul style="list-style-type: none"> <li>• If younger than age 13yrs, space dose #1 and #2 at least 3m apart. If age 13yrs or older, space at least 4wks apart.</li> <li>• May use as postexposure prophylaxis if given within 5d.</li> <li>• If Var and either MMR, LAIV, and/or yellow fever vaccine are not given on the same day, space them at least 28d apart.</li> </ul>	<p><b>Contraindications</b></p> <ul style="list-style-type: none"> <li>• Previous anaphylaxis to this vaccine or to any of its components.</li> <li>• Pregnancy or possibility of pregnancy within 4wks.</li> <li>• Children on high-dose immunosuppressive therapy or who are immunocompromised because of malignancy and primary or acquired cellular immunodeficiency, including HIV/AIDS (although vaccination may be considered if CD4+ T-lymphocyte percentages are either 15% or greater in children ages 1 through 8yrs or 200 cells/μL or greater in children age 9yrs and older).</li> </ul> <p><b>Precautions</b></p> <ul style="list-style-type: none"> <li>• Moderate or severe acute illness.</li> <li>• If blood, plasma, and/or immune globulin (IG or VZIG) were given in past 11m, see ACIP statement <i>General Recommendations on Immunization*</i> regarding time to wait before vaccinating.</li> <li>• Receipt of specific antivirals (i.e., acyclovir, famciclovir, or valacyclovir) 24hrs before vaccination, if possible; delay resumption of these antiviral drugs for 14d after vaccination.</li> <li>• For MMRV only, personal or family (i.e., sibling or parent) history of seizures.</li> </ul> <p><b>Note:</b> For patients with humoral immunodeficiency or leukemia, see ACIP recommendations*.</p>
<p><b>MMR</b> (Measles, mumps, rubella) <i>Give SC</i></p>	<ul style="list-style-type: none"> <li>• Give dose #1 at age 12–15m.</li> <li>• Give dose #2 at age 4–6yrs. Dose #2 may be given earlier if at least 4wks since dose #1.</li> <li>• Give a 2nd dose to all older children and teens with history of only 1 dose.</li> <li>• MMRV may be used in children age 12m through 12yrs.</li> <li>• MMRV generally is preferred over separate injections of its separate components in children receiving their first dose at ages 4 through 12yrs or their second dose at any age through 12yrs.</li> </ul>	<ul style="list-style-type: none"> <li>• If MMR and either Var, LAIV, and/or yellow fever vaccine are not given on the same day, space them at least 28d apart.</li> <li>• When using MMR for both doses, minimum interval is 4wks.</li> <li>• When using MMRV for both doses, minimum interval is 3m.</li> <li>• Within 72hrs of measles exposure, give 1 dose of MMR as postexposure prophylaxis to susceptible healthy children age 12m and older.</li> </ul>	<p><b>Contraindications</b></p> <ul style="list-style-type: none"> <li>• Previous anaphylaxis to this vaccine or to any of its components.</li> <li>• Pregnancy or possibility of pregnancy within 4wks.</li> <li>• Severe immunodeficiency (e.g., hematologic and solid tumors; receiving chemotherapy; congenital immunodeficiency; long-term immunosuppressive therapy, or severely symptomatic HIV). Note: HIV infection is NOT a contraindication to MMR for children who are not severely immunocompromised (consult ACIP MMR recommendations [MMWR 1998;47 [RR-8] for details*).</li> </ul> <p><b>Precautions</b></p> <ul style="list-style-type: none"> <li>• Moderate or severe acute illness.</li> <li>• If blood, plasma, or immune globulin given in past 11m, see ACIP statement <i>General Recommendations on Immunization*</i> regarding time to wait before vaccinating.</li> <li>• History of thrombocytopenia or thrombocytopenic purpura.</li> <li>• For MMRV only, personal or family (i.e., sibling or parent) history of seizures.</li> </ul> <div style="border: 1px solid black; border-radius: 15px; padding: 5px; margin-top: 10px;"> <p><b>Note:</b> MMR is not contraindicated if a TST (tuberculosis skin test) was recently applied. If TST and MMR are not given on same day, delay TST for at least 4wks after MMR.</p> </div>

# Summary of Recommendations for Childhood and Adolescent Immunization

Vaccine name and route	Schedule for routine vaccination and other guidelines (any vaccine can be given with another)	Schedule for catch-up vaccination and related issues	Contraindications and precautions (mild illness is not a contraindication)
<p><b>Hib</b> <i>(Haemophilus influenzae type b)</i> Give IM</p>	<ul style="list-style-type: none"> <li>• ActHib (PRP-T): give at age 2m, 4m, 6m, 12–15m (booster dose).</li> <li>• PedvaxHIB or Comvax (containing PRP-OMP): give at age 2m, 4m, 12–15m (booster dose).</li> <li>• Dose #1 of Hib vaccine should not be given earlier than age 6wks.</li> <li>• The last dose (booster dose) is given no earlier than age 12m and a minimum of 8wks after the previous dose.</li> <li>• Hib vaccines are interchangeable; however, if different brands of Hib vaccines are administered for dose #1 and dose #2, a total of 3 doses are necessary to complete the primary series in infants.</li> <li>• Any Hib vaccine may be used for the booster dose.</li> <li>• Hib is not routinely given to children age 5yrs and older.</li> <li>• Hiberix is approved ONLY for the booster dose at age 15m through 4yrs.</li> </ul>	<p><b>All Hib vaccines:</b></p> <ul style="list-style-type: none"> <li>• If #1 was given at 12–14m, give booster in 8wks.</li> <li>• Give only 1 dose to unvaccinated children ages 15 through 59m.</li> </ul> <p><b>ActHib:</b></p> <ul style="list-style-type: none"> <li>• #2 and #3 may be given 4wks after previous dose.</li> <li>• If #1 was given at age 7–11m, only 3 doses are needed; #2 is given 4–8wks after #1, then boost at age 12–15m (wait at least 8wks after dose #2).</li> </ul> <p><b>PedvaxHIB and Comvax:</b></p> <ul style="list-style-type: none"> <li>• #2 may be given 4wks after dose #1.</li> </ul>	<p><b>Contraindications</b></p> <ul style="list-style-type: none"> <li>• Previous anaphylaxis to this vaccine or to any of its components.</li> <li>• Age younger than 6wks.</li> </ul> <p><b>Precaution</b> Moderate or severe acute illness.</p>
<p><b>Pneumococcal conjugate (PCV13)</b> Give IM</p>	<p>As soon as feasible, replace existing stock of PCV7 with PCV13.</p> <ul style="list-style-type: none"> <li>• Give at ages 2m, 4m, 6m, 12–15m.</li> <li>• Dose #1 may be given as early as age 6wks.</li> <li>• When children are behind on PCV schedule, minimum interval for doses given to children younger than age 12m is 4wks; for doses given at 12m and older is 8wks.</li> <li>• Give 1 dose to unvaccinated healthy children age 24–59m.</li> <li>• For high-risk** children ages 24–71m: Give 2 doses at least 8wks apart if they previously received fewer than 3 doses; give 1 dose at least 8wks after the most recent dose if they previously received 3 doses.</li> <li>• PCV13 is not routinely given to healthy children age 5yrs and older.</li> </ul> <div style="border: 1px solid black; border-radius: 15px; padding: 10px; margin-top: 10px;"> <p><b>**High-risk:</b> Those with sickle cell disease; anatomic or functional asplenia; chronic cardiac, pulmonary, or renal disease; diabetes; cerebrospinal fluid leaks; HIV infection; immunosuppression; diseases associated with immunosuppressive and/or radiation therapy; or who have or will have a cochlear implant.</p> </div>	<ul style="list-style-type: none"> <li>• For minimum intervals, see bullet #3 at left.</li> <li>• For age 7–11m: If history of 0 doses, give 2 doses 4wks apart, with a 3rd dose at age 12–15m; if history of 1 or 2 doses, give 1 dose with a 2nd dose at age 12–15m.</li> <li>• For age 12–23m: If unvaccinated or history of 1 dose before age 12m, give 2 doses 8wks apart; if history of 1 dose at or after age 12m or 2 or 3 doses before age 12m, give 1 dose at least 8wks after most recent dose.</li> <li>• For age 24–59m and healthy: If unvaccinated or any incomplete schedule or if 4 doses of PCV7 or any other age-appropriate complete PCV7 schedule, give 1 dose at least 8wks after the most recent dose.</li> <li>• For age 24–71m and at high risk**: If unvaccinated or any incomplete schedule of 1 or 2 doses, give 2 doses, 1 at least 8wks after the most recent dose and another dose at least 8wks later; if any incomplete series of 3 doses, or if 4 doses of PCV7 or any other age-appropriate complete PCV7 schedule, give 1 dose at least 8wks after the most recent dose.</li> <li>• For children ages 6 through 18yrs with functional or anatomic asplenia (including sickle cell disease), HIV infection or other immunocompromising condition, cochlear implant, or CSF leak, consider giving 1 dose of PCV13 regardless of previous history of PCV7 or PPSV.</li> </ul>	<p><b>Contraindication</b> Previous anaphylaxis to a PCV vaccine, to any of its components, or to any diphtheria toxoid-containing vaccine.</p> <p><b>Precaution</b> Moderate or severe acute illness.</p>
<p><b>Pneumococcal polysaccharide (PPSV)</b> Give IM or SC</p>	<ul style="list-style-type: none"> <li>• Give 1 dose at least 8wks after final dose of PCV to high-risk children age 2yrs and older.</li> <li>• For children who are immunocompromised or have sickle cell disease or functional or anatomic asplenia, give a 2nd dose of PPSV 5yrs after previous PPSV (consult ACIP PPSV recommendations at <a href="http://www.cdc.gov/vaccines/pubs/ACIP-list.htm">www.cdc.gov/vaccines/pubs/ACIP-list.htm</a>).</li> </ul>		<p><b>Contraindication</b> Previous anaphylaxis to this vaccine or to any of its components.</p> <p><b>Precaution</b> Moderate or severe acute illness.</p>

# Summary of Recommendations for Childhood and Adolescent Immunization

Vaccine name and route	Schedule for routine vaccination and other guidelines (any vaccine can be given with another)	Schedule for catch-up vaccination and related issues	Contraindications and precautions (mild illness is not a contraindication)
<b>Rotavirus (RV)</b> <i>Give orally</i>	<ul style="list-style-type: none"> <li>• Rotarix (RV1): give at age 2m, 4m.</li> <li>• RotaTeq (RV5): give at age 2m, 4m, 6m.</li> <li>• May give dose #1 as early as age 6wks.</li> <li>• Give final dose no later than age 8m 0 days.</li> </ul>	<ul style="list-style-type: none"> <li>• Do not begin series in infants older than age 15wks 0 days.</li> <li>• Intervals between doses may be as short as 4wks.</li> <li>• If prior vaccination included use of different or unknown brand(s), a total of 3 doses should be given.</li> </ul>	<p><b>Contraindication</b> Previous anaphylaxis to this vaccine or to any of its components. If allergy to latex, use RV5.</p> <p><b>Precautions</b></p> <ul style="list-style-type: none"> <li>• Moderate or severe acute illness.</li> <li>• Altered immunocompetence.</li> <li>• Moderate to severe acute gastroenteritis or chronic pre-existing gastrointestinal disease.</li> <li>• History of intussusception.</li> </ul>
<b>Hepatitis A (HepA)</b> <i>Give IM</i>	<ul style="list-style-type: none"> <li>• Give 2 doses spaced 6m apart to all children at age 1yr (12–23m).</li> <li>• Vaccinate all previously unvaccinated children and adolescents age 2yrs and older who               <ul style="list-style-type: none"> <li>- Want to be protected from HAV infection.</li> <li>- Live in areas where vaccination programs target older children.</li> <li>- Travel anywhere except U.S., W. Europe, N. Zealand, Australia, Canada, or Japan.</li> <li>- Have chronic liver disease, clotting factor disorder, or are adolescent males who have sex with other males.</li> <li>- Are users of illicit drugs (injectable or non-injectable).</li> <li>- Anticipate close personal contact with an international adoptee from a country of high or intermediate endemicity during the first 60 days following the adoptee’s arrival in the U.S.</li> </ul> </li> </ul>	<ul style="list-style-type: none"> <li>• Minimum interval between doses is 6m.</li> <li>• Children who are not fully vaccinated by age 2yrs can be vaccinated at subsequent visits.</li> <li>• Consider routine vaccination of children age 2yrs and older in areas with no existing program.</li> <li>• Give 1 dose as postexposure prophylaxis to incompletely vaccinated children age 12m and older who have recently (during the past 2wks) been exposed to hepatitis A virus.</li> </ul>	<p><b>Contraindication</b> Previous anaphylaxis to this vaccine or to any of its components.</p> <p><b>Precautions</b></p> <ul style="list-style-type: none"> <li>• Moderate or severe acute illness.</li> <li>• Pregnancy.</li> </ul>
<b>Meningococcal conjugate (MCV4)</b> Menactra (ages 2–55yrs) Menveo (ages 11–55yrs) <i>Give IM</i> <b>Meningococcal polysaccharide (MPSV4)</b> <i>Give SC</i>	<ul style="list-style-type: none"> <li>• Give 1-time dose of MCV4 to adolescents age 11 through 18yrs.</li> <li>• Vaccinate all college freshmen living in dorms who have not been vaccinated.</li> <li>• Vaccinate all children age 2yrs and older who have any of the following risk factors:               <ul style="list-style-type: none"> <li>- Anatomic or functional asplenia, or persistent complement component deficiency.</li> <li>- Travel to or reside in countries in which meningococcal disease is hyperendemic or epidemic (e.g., the “meningitis belt” of Sub-Saharan Africa).</li> <li>- Military recruits</li> </ul> </li> </ul> <p><b>Note:</b> Use MPSV4 ONLY if there is a permanent contraindication or precaution to MCV4.</p>	<p>If previously vaccinated with MPSV4 or MCV4 and risk of meningococcal disease persists, revaccinate with Menactra in 3yrs (if first dose given at age 2 through 6yrs) or revaccinate with either brand of MCV4 after 5yrs (if previous dose given at age 7yrs or older). If the only risk factor is living in a campus dormitory, there is no need to give a 2nd dose if previous dose was MCV4.</p>	<p><b>Contraindication</b> Previous anaphylaxis to any any meningococcal vaccine or to any of its components, including diphtheria toxoid (for MCV4).</p> <p><b>Precautions</b></p> <ul style="list-style-type: none"> <li>• Moderate or severe acute illness.</li> <li>• For MCV4 only: history of Guillain-Barré syndrome (if not at extremely high risk for meningococcal disease).</li> <li>• In pregnancy, studies of vaccination with MPSV4 have not documented adverse effects so may use MPSV4 if indicated. No data are available on the safety of MCV4 during pregnancy.</li> </ul>
<b>Human papillomavirus HPV</b> (HPV2, Cervarix) (HPV4, Gardasil) <i>Give IM</i>	<ul style="list-style-type: none"> <li>• Give 3-dose series to girls at age 11–12yrs on a 0, 1–2, 6m schedule. (May be given as early as age 9yrs.)</li> <li>• Vaccinate all older girls and women (through age 26yrs) who were not previously vaccinated.</li> <li>• Consider giving HPV4 to males age 9 through 26yrs to reduce their likelihood of acquiring genital warts.</li> </ul>	<p>Minimum intervals between doses: 4wks between #1 and #2; 12 wks between #2 and #3. Overall, there must be at least 24wks between doses #1 and #3. If possible, use the same vaccine product for all doses.</p>	<p><b>Contraindication</b> Previous anaphylaxis to this vaccine or to any of its components.</p> <p><b>Precautions</b></p> <ul style="list-style-type: none"> <li>• Moderate or severe acute illness.</li> <li>• Pregnancy.</li> </ul>